Back to search results

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

This study is looking at how two antiarrhythmic drugs, flecainide and sotalol, work in people with atrial fibrillation (AF), a condition where your heart beats irregularly. Researchers want to see if your genes might affect how well these medicines control your AF. You could be eligible if you are 18 to 100 years old, have frequent AF episodes, and can take both flecainide and sotalol. The main goal is to measure how much time you spend in AF over 12 months while taking these medications. The current status of this study is unclear.

Study design
This is a pilot study involving 162 participants with atrial fibrillation, comparing two different antiarrhythmic drugs.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, AF burden, will be measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02347111

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Recruiting
PHASE4Ages 18+InterventionalTreatment
University of Illinois at Chicago
~162 participants
Updated 2025-08-24 on ClinicalTrials.gov
What's tested:FlecainideSotalol

At a glance

Recruiting sites
1 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
AF burden (Percent of time subject is in atrial fibrillation)
Measured over 12 months

Conditions

Atrial Fibrillation

Explore related trials

Atrial Fibrillation

NCT02347111

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Advocate Christ Medical Center

    Oak Lawn, Illinoisstudy coordinator listed

    Not yet recruiting

  • Jesse Brown VA Medical Center

    Chicago, Illinoisstudy coordinator listed

    Not yet recruiting

  • Rush University Medical Center

    Chicago, Illinoisstudy coordinator listed

    Not yet recruiting

  • University of Illinois at Chicago

    Chicago, Illinoisstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Dawood Darbar, M.D.
[email protected]
6158879032
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥ 18 years of age
History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
ECG that was recorded within 1 month of randomization showing AF
Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
Able to give informed consent

Exclusion

Permanent AF or isolated atrial flutter
Cardiac or thoracic surgery within the previous 6 months
Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
Medical condition that is likely to be fatal in less than one year
A history of prior AF ablation
Have already been tried on 2 or more AADs in the past for AF
Creatinine clearance \<40 ml/min
Left ventricular ejection fraction \< 50%
Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI
Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc\>480 ms in females and \>460 ms in males at baseline
A reversible cause of AF (e.g., hyperthyroidism)
Females who are pregnant or nursing
History of severe AV node dysfunction unless an electronic pacemaker is present
First- or second-degree relative has already participated in the study
Unable to adhere to study procedures that are strictly for research purposes

What this trial measures

  • AF burden (Percent of time subject is in atrial fibrillation)12 months

    Subjects will be monitored with the Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) system to assess AF burden. The device will be programmed to optimize the memory for storing AF episode.